Eli Lilly and Company $LLY Stock Position Decreased by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 15.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,603 shares of the company’s stock after selling 12,792 shares during the period. Eli Lilly and Company accounts for about 1.1% of Kingsview Wealth Management LLC’s investment portfolio, making the stock its 15th largest position. Kingsview Wealth Management LLC’s holdings in Eli Lilly and Company were worth $75,876,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Smith Chas P & Associates PA Cpas raised its stake in shares of Eli Lilly and Company by 133.5% during the 4th quarter. Smith Chas P & Associates PA Cpas now owns 1,214 shares of the company’s stock worth $1,305,000 after purchasing an additional 694 shares in the last quarter. Barry Investment Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $325,000. Severin Investments LLC raised its stake in shares of Eli Lilly and Company by 3.2% during the 4th quarter. Severin Investments LLC now owns 702 shares of the company’s stock worth $755,000 after purchasing an additional 22 shares in the last quarter. PSI Advisors LLC raised its stake in shares of Eli Lilly and Company by 4.0% during the 4th quarter. PSI Advisors LLC now owns 5,524 shares of the company’s stock worth $5,937,000 after purchasing an additional 214 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc raised its stake in shares of Eli Lilly and Company by 10.3% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 13,533 shares of the company’s stock worth $14,544,000 after purchasing an additional 1,264 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,085.36 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business’s 50 day moving average is $948.23 and its two-hundred day moving average is $1,007.67. The company has a market cap of $1.02 trillion, a P/E ratio of 38.56, a P/E/G ratio of 1.16 and a beta of 0.48. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the firm earned $3.34 EPS. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Bank of America raised their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research note on Tuesday. CICC Research raised their price objective on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Leerink Partners set a $1,119.00 price objective on Eli Lilly and Company in a research note on Tuesday. Finally, Weiss Ratings downgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company in a combined deal worth up to $3.83 billion, expanding its vaccine and infectious-disease pipeline. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: The acquisition spree is being viewed as a strategic move to diversify Lilly’s business and leverage the cash flow generated by its obesity franchise into adjacent high-value markets. Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
• Positive Sentiment: LLY has also been hitting record highs and became the first pharmaceutical company valued at $1 trillion, reinforcing the market’s confidence in its growth story. Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion
• Neutral Sentiment: Additional coverage highlighted continued investor attention around Lilly’s momentum, analyst optimism, and its participation in a Goldman Sachs healthcare conference, but these items are less likely to move the stock on their own. Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Articles comparing Lilly with Novo Nordisk and discussing Trump’s stock purchases do not appear to change the core investment thesis, with Lilly’s fundamentals still seen as the main driver. President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
• Neutral Sentiment: Competition concerns around Novo Nordisk in the obesity-pill market were framed as manageable rather than a major threat. Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.